Moreover, up to 80% of low-grade NMIBC tumours show the fibroblast growth factor receptor 3 (FGFR3) gene mutationwith a constitutively active receptor tyrosine kinase–Ras pathway[37–39]. The gene discussed is FGFR3; the disease is neoplasm.